BCVA, anatomic improvements found with OPT-302 combination therapy for PCV

At ARVO 2022, Dr Jason S. Slakter presents data on the efficacy and safety of OPT-302 when combined with ranibizumab for polypoidal choroidal vasculopathy.

Emily Kaiser, editor of Modern Retina™, sits down with Dr Jason S. Slakter to discuss his ARVO 2022 presentation, “Efficacy and Safety of OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy.” OPT-302 (Opthea Limited) 2 mg combination therapy results indicated a safety profile consistent with the standard of care anti-VEGF-A monotherapy, but also indicated superior improvements in best-corrected visual acuity (BCVA) and anatomic improvements compared to monthly ranibizumab (Lucentis®) monotherapy in patients with polypoidal choroidal vasculopathy (PCV).

Related Videos
Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase
Trukera Medical rebranding ushers in new era of expansion into cornea market
2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent
Younger patients often require repeat corneal crosslinking, study finds
Investigators report positive visual outcomes one year after monocular implantation of small aperture IOL
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
Utilising AAO cornea preferred practice patterns for corneal oedema, opacifications, ectasia and bacterial keratits
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
© 2023 MJH Life Sciences

All rights reserved.